In in vitro testing, venadaparib exhibited superior inhibitory activity against BRCA‐mutated cancer cell lines compared to other PARP inhibitors and high specificity in inhibiting the growth of HR‐deficient cancer cells [19, 20]. This evidence concerns the gene PARP1 and cancer.